HEMO BIOENGINEERING LIMITED (the “Company” and collectively with its subsidiaries, “HEMO”) is committed to developing and providing innovative interventional medical devices to patients to improve their health and quality of life.

We have built a suite of interventional medical devices targeting peripheral and neuro-vascular diseases primarily in China and APAC, and both peripheral and neurovascular medical devices have been our key focuses.  

Our portfolio of neuro-interventional medical devices covers all of the ischemic stroke, hemorrhagic stroke and neuro access fields. We have a first-mover advantage in mechanical thrombectomy in China for acute ischemic stroke evidenced by our first-to-market domestic aspiration catheter Afentta®, which is the first domestic aspiration catheter approved by the NMPA and commercialized in China.

Headquartered in Singapore, our current businesses are principally based in China where we have established R&D and production facilities in Weihai and offices in Beijing and Shanghai.  Our global R&D resources also include R&D centres in Singapore and the U.S. as well as a network of key opinion leaders and industry experts.  We were founded by our Executive Director, Chairman, CEO and CTO Dr. Jack Wang, an industry veteran and seasoned entrepreneur who had previously served as CEO at both SGX Mainboard-listed Biosensors International Group and JW Medical Systems.